Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

Inclusion Criteria: * Females of couples with an indication for COH and IVF or IVF/ICSI; * Body mass index (BMI) \>=18 and \<=29 kg/m\^2; * Normal menstrual cycle length: 24-35 days; * Ejaculatory sperm; Exclusion Criteria: * History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS), or polycystic ovaries according to ultrasound scan (USS), (treated) hyperprolactinemia or evidence of ovarian dysfunction; * More than three unsuccessful COH cycles for IVF since the last established ongoing pregnancy (if applicable); * History of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment; * Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual Cycle Day 2-7) as measured by the local laboratory (FSH, luteinizing hormone \[LH\], estradiol \[E2\], progesterone \[P\], total testosterone \[T\], thyroid stimulating hormone \[TSH\], and prolactin); * Any clinically relevant abnormal laboratory value; * Any ovarian and/or abdominal abnormality interfering with ultrasound examination; * Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts); * Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease; * History or presence of alcohol or drug abuse within 12 months prior to signing informed consent; * Hypersensitivity to Orgalutran® or any of its components; * Administration of investigational drugs within three months prior to screening. * Use of hormonal preparations within one month prior to the start of Org 36286 with the exception of thyroid medication.